201-300

201. Libby P, Bonow RO, Mann DL , et al. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine (9th edition). Saunders 2011: 1254.

202. Cheng TO, Bashour T, Singh BK, et al. Myocardial infarction in the absence of coronary arteriosclerosis. Result of coronary spasm (?). Am J Cardiol

1972; 30: 680-682.

203. Rigatelli G, Rossi P, Docali G. Normal angiogram in acute coronary syndromes: the underestimated role of alternative substrates of myocardial

ischemia. Int J Cardiovasc Imaging 2004; 20: 471-475.

204. Burke AP, Virmani R. Pathophysiology of acute myocardial infarction. Med Clin North Am 2007; 91: 553-572; ix.

205. Prizel KR, Hutchins GM, Bulkley BH. Coronary artery embolism and myocardial infarction. Ann Intern Med 1978; 88: 155-161.

206. Hancock EW. Aortic stenosis, angina pectoris, and coronary artery disease. Am Heart J 1977; 93: 382-393.

207. Chlapoutakis GN, Kafkas NV, Katsanos SM, et al. Acute myocardial infarction and transient ischemic attack in a patient with lone atrial fibrillation and

normal coronary arteries. Int J Cardiol 2010; 139: e1-4.

208. Karanasos A, Tsiamis E, Stefanadis C. Myocardial infarction caused by ostial right coronary artery thrombus in the absence of atheromatosis.

J Invasive Cardiol 2012; 24: E188-189.

209. Vincent GM, Anderson JL, Marshall HW. Coronary spasm producing coronary thrombosis and myocardial infarction. N Engl J Med 1983; 309:

220-223.

210. Lin CS, Penha PD, Zak FG, et al. Morphodynamic interpretation of acute coronary thrombosis, with special reference to volcanolike eruption of

atheromatous plaque caused by coronary artery spasm. Angiology 1988; 39: 535-547.

211. Ueda Y, Hirayama A, Kodama K. Plaque characterization and atherosclerosis evaluation by coronary angioscopy. Herz 2003; 28: 501-504.

212. Oshima S, Yasue H, Ogawa H, et al. Fibrinopeptide A is released into the coronary circulation after coronary spasm. Circulation 1990; 82: 2222-2225.

213. Misumi I, Ogawa H, Masuda T, et al. Increased plasma plasminogen activator inhibitor activity after coronary spasm. Int J Cardiol 1993; 41: 21-29.

214. Kaikita K, Ogawa H, Yasue H, et al. Soluble P-selectin is released into the coronary circulation after coronary spasm. Circulation 1995; 92:

1726-1730.

215. Bertrand ME, Lablanche JM, Tilmant PY, et al. The provocation of coronary arterial spasm in patients with recent transmural myocardial infarction. Eur

Heart J 1983; 4: 532-535.

216. Mongiardo R, Finocchiaro ML, Beltrame J, et al. Low incidence of serotonin-induced occlusive coronary artery spasm in patients with recent

myocardial infarction. Am J Cardiol 1996; 78: 84-87.

217. Bonnefoy E, Lapostolle F, Leizorovicz A, et al. Primary angioplasty versus prehospital fibrinolysis in acute myocardial infarction: a randomised study.

Lancet 2002; 360: 825-829.

218. Widimsky P, Budesinsky T, Vorac D, et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction.

Final results of the randomized national multicentre trial―PRAGUE-2. Eur Heart J 2003; 24: 94-104.

219. Ui S, Chino M, Isshiki T. Rates of primary percutaneous coronary intervention worldwide. Circ J 2005; 69: 95-100.

220. Ogawa H, Kojima S. Modern state of acute myocardial infarction in the interventional era: observational case-control study―Japanese acute coronary

syndrome study (JACSS). J Cardiol 2009; 54: 1-9.

221. Steg PG, Bonnefoy E, Chabaud S, et al. Impact of time to treatment on mortality after prehospital fibrinolysis or primary angioplasty: data from the

CAPTIM randomized clinical trial. Circulation 2003; 108: 2851-2856.

222. Antman EM. General hospital management. In: Julian DG, Braunwald E, eds. Management of acute myocardial infarction. WB Saunders 1994; 42-44.

223. Lincoff AM, Califf RM, Van de Werf F, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic

therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002; 288: 2130-2135.

224. Zijlstra F, Beukema WP, van't Hof AW, et al. Randomized comparison of primary coronary angioplasty with thrombolytic therapy in low risk patients

with acute myocardial infarction. J Am Coll Cardiol 1997; 29: 908-912.

225. Zijlstra F, de Boer MJ, Hoorntje JC, et al. A comparison of immediate coronary angioplasty with intravenous streptokinase in acute myocardial

infarction. N Engl J Med 1993; 328: 680-684.

226. Widimsky P, Groch L, Zelizko M, et al. Multicentre randomized trial comparing transport to primary angioplasty vs immediate thrombolysis vs

combined strategy for patients with acute myocardial infarction presenting to a community hospital without a catheterization laboratory. The

PRAGUE study. Eur Heart J 2000; 21: 823-831.

227. de Boer MJ, Ottervanger JP, van't Hof AW, et al. Zwolle Myocardial Infarction Study Group. Reperfusion therapy in elderly patients with acute

myocardial infarction: a randomized comparison of primary angioplasty and thrombolytic therapy. J Am Coll Cardiol 2002; 39: 1723-1728.

228. Akhras F, Ousa AA, Swann G, et al. Primary coronary angioplasty or intravenous thrombolysis for patients with acute myocardial infarction? Acute

and late follow-up results in a new cardiac unit. J Am Coll Cardiol 1997; 29: A235-A236.

229. Grines CL, Browne KF, Marco J, et al. A comparison of immediate angioplasty with thrombolytic therapy for acute myocardial infarction. The Primary

Angioplasty in Myocardial Infarction Study Group. N Engl J Med 1993; 328: 673-679.

230. Ribichini F, Steffenino G, Dellavalle A, et al. Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior

myocardial infarction with precordial STsegment depression: immediate and long-term results of a randomized study. J Am Coll Cardiol 1998; 32:

1687-1694.

231. Garcia E, Elizaga J, Perez-Castellano N, et al. Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction. J Am Coll Cardiol

1999; 33: 605-611.

232. A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. The Global Use of Strategies

to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO IIb) Angioplasty Substudy Investigators. N Engl J Med 1997; 336: 1621-

1628.

233. Schomig A, Kastrati A, Dirschinger J, et al. Coronary stenting plus platelet glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator

in acute myocardial infarction. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study

Investigators. N Engl J Med 2000; 343: 385-391.

234. Vermeer F, Oude Ophuis AJ, vd Berg EJ, et al. Prospective randomised comparison between thrombolysis, rescue PTCA, and primary PTCA in

patients with extensive myocardial infarction admitted to a hospital without PTCA facilities: a safety and feasibility study. Heart 1999; 82: 426-431.

235. Kastrati A, Mehilli J, Dirschinger J, et al. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients With Acute Myocardial Infarction

(STOPAMI-2) Study. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial

infarction: a randomised trial. Lancet 2002; 359: 920-925.

236. Aversano T, Aversano LT, Passamani E, et al. Thrombolytic therapy vs primary percutaneous coronary intervention for myocardial infarction in patients

presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA 2002; 287: 1943-1951.

237. Grines CL, Westerhausen DR, Grines LL, et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-

risk myocardial infarction: the Air Primary Angioplasty in Myocardial Infarction study. J Am Coll Cardiol 2002; 39: 1713-1719.

238. Andersen HR, Nielsen TT, Rasmussen K, et al. DANAMI-2 Investigators. A comparison of coronary angioplasty with fibrinolytic therapy in acute

myocardial infarction. N Engl J Med 2003; 349: 733-742.

239. Gibbons RJ, Holmes DR, Reeder GS, et al. Immediate angioplasty compared with the administration of a thrombolytic agent followed by conservative

treatment for myocardial infarction. The Mayo Coronary Care Unit and Catheterization Laboratory Groups. N Engl J Med 1993; 328: 685-691.

240. Mori T, Nosaka H, Kimura T, et al. Long-term follow-up of patients treated with intracoronary thrombolysis or percutaneous transluminal coronary

angioplasty for acute myocardial infarction. J Cardiol 1991; 21: 323-336. (in Japanese)

241. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review

of 23 randomised trials. Lancet 2003; 361: 13-20.

242. Nordmann AJ, Hengstler P, Harr T, et al. Clinical outcomes of primary stenting versus balloon angioplasty in patients with myocardial infarction: a

meta-analysis of randomized controlled trials. Am J Med 2004; 116: 253-262.

243. Zhu MM, Feit A, Chadow H, et al. Primary stent implantation compared with primary balloon angioplasty for acute myocardial infarction: a meta-

analysis of randomized clinical trials. Am J Cardiol 2001; 88: 297-301.

244. Stone GW, Lansky AJ, Pocock SJ, et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009; 360:

1946-1959.

245. Kastrati A, Dibra A, Spaulding C, et al. Meta-analysis of randomized trials on drug-eluting stents vs. bare-metal stents in patients with acute

myocardial infarction. Eur Heart J 2007; 28: 2706-2713.

246. Singh M, Holmes DR, Dehmer GJ, et al. Percutaneous coronary intervention at centers with and without on-site surgery: a metaanalysis. JAMA

2011; 306: 2487-2494.

247. Dzavik V, Sleeper LA, Cocke TP, et al. Early revascularization is associated with improved survival in elderly patients with acute myocardial infarction

complicated by cardiogenic shock: a report from the SHOCK Trial Registry. Eur Heart J 2003; 24: 828-837.

248. Dauerman HL, Goldberg RJ, Malinski M, et al. Outcomes and early revascularization for patients > or = 65 years of age with cardiogenic shock. Am

J Cardiol 2001; 87: 844-848.

249. Svilaas T, Vlaar PJ, van der Horst IC, et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008; 358: 557-567.

250. Ikari Y, Sakurada M, Kozuma K, et al. Upfront thrombus aspiration in primary coronary intervention for patients with ST-segment elevation acute

myocardial infarction: report of the VAMPIRE (VAcuuM asPIration thrombus REmoval) trial. JACC Cardiovasc Interv 2008; 1: 424-431.

251. Nakatani D, Sato H, Sakata Y, et al. Effect of intracoronary thrombectomy on 30-day mortality in patients with acute myocardial infarction.

Am J Cardiol 2007; 100: 1212-1217.

252. Burzotta F, De Vita M, Gu YL, et al. Clinical impact of thrombectomy in acute ST-elevation myocardial infarction: an individual patient-data pooled

analysis of 11 trials. Eur Heart J 2009; 30: 2193-2203.

253. Stone GW, Maehara A, Witzenbichler B, et al. Intracoronary abciximab and aspiration thrombectomy in patients with large anterior myocardial

infarction: the INFUSE-AMI randomized trial. JAMA 2012; 307: 1817-1826.

254. Stone GW, Webb J, Cox DA, et al. Distal microcirculatory protection during percutaneous coronary intervention in acute ST-segment elevation

myocardial infarction: a randomized controlled trial. JAMA 2005; 293: 1063-1072.

255. Bavry AA, Kumbhani DJ, Bhatt DL. Role of adjunctive thrombectomy and embolic protection devices in acute myocardial infarction: a comprehensive

meta-analysis of randomized trials. Eur Heart J 2008; 29: 2989-3001.

256. Fernandez-Aviles F, Alonso JJ, Pena G, et al. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with

ST-segment elevation: the GRACIA-2 noninferiority, randomized, controlled trial. Eur Heart J 2007; 28: 949-960.

257. Armstrong PW, Committee WS. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous

intervention early after ST-elevation myocardial infarction: the WEST (Which Early ST-elevation myocardial infarction Therapy) study. Eur Heart J

2006; 27: 1530-1538.

258. Kjaergard H, Nielsen PH, Andreasen JJ, et al. Coronary artery bypass grafting within 30 days after treatment of acute myocardial infarctions with

angioplasty or fibrinolysis - a surgical substudy of DANAMI-2. Scand Cardiovasc J 2004; 38: 143-146.

259. Stone GW, Brodie BR, Griffin JJ, et al. Role of cardiac surgery in the hospital phase management of patients treated with primary angioplasty for acute

myocardial infarction. Am J Cardiol 2000; 85: 1292-1296.

260. Filizcan U, Kurc E, Cetemen S, et al. Mortality predictors in ST-elevated myocardial infarction patients undergoing coronary artery bypass grafting.

Angiology 2011; 62: 68-73.

261. Creswell LL, Moulton MJ, Cox JL, et al. Revascularization after acute myocardial infarction. Ann Thorac Surg 1995; 60: 19-26.

262. Kamohara K, Yoshikai M, Yunoki J, et al. Surgical revascularization for acute coronary syndrome: comparative surgical and long-term results. Jpn J

Thorac Cardiovasc Surg 2006; 54: 95-102.

263. Kjaergard HK, Nielsen PH, Andreasen JJ, et al. Coronary artery bypass grafting within the first year after treatment of large acute myocardial

infarctions with angioplasty or fibrinolysis. Scand Cardiovasc J 2006; 40: 25-28.

264. Lee DC, Oz MC, Weinberg AD, et al. Optimal timing of revascularization: transmural versus nontransmural acute myocardial infarction. Ann Thorac

Surg 2001; 71: 1197-1202; discussion 1202-1194.

265. Wasvary H, Shannon F, Bassett J, et al. Timing of coronary artery bypass grafting after acute myocardial infarction. Am Surg 1997; 63: 710-715.

266. Weiss ES, Chang DD, Joyce DL, et al. Optimal timing of coronary artery bypass after acute myocardial infarction: a review of California discharge

data. J Thorac Cardiovasc Surg 2008; 135: 503-511, 511.e501-503.

267. Lee JH, Murrell HK, Strony J, et al. Risk analysis of coronary bypass surgery after acute myocardial infarction. Surgery 1997; 122: 675-680;

discussion 680-671.

268. Lee DC, Oz MC, Weinberg AD, et al. Appropriate timing of surgical intervention after transmural acute myocardial infarction. J Thorac Cardiovasc Surg

2003; 125: 115-119; discussion 119-120.

269. Donatelli F, Benussi S, Triggiani M, et al. Surgical treatment for life-threatening acute myocardial infarction: a prospective protocol. Eur J Cardiothorac

Surg 1997; 11: 228-233.

270. Mehta RH, Lopes RD, Ballotta A, et al. Percutaneous coronary intervention or coronary artery bypass surgery for cardiogenic shock and multivessel

coronary artery disease? Am Heart J 2010; 159: 141-147.

271. White HD, Assmann SF, Sanborn TA, et al. Comparison of percutaneous coronary intervention and coronary artery bypass grafting after acute

myocardial infarction complicated by cardiogenic shock: results from the Should We Emergently Revascularize Occluded Coronaries for Cardiogenic

Shock (SHOCK) trial. Circulation 2005; 112: 1992-2001.

272. Puskas J, Cheng D, Knight J, et al. Off-Pump versus Conventional Coronary Artery Bypass Grafting: A Meta-Analysis and Consensus Statement From

The 2004 ISMICS Consensus Conference. Innovations (Phila) 2005; 1: 3-27.

273. Hohnloser SH, Zabel M, Kasper W, et al. Assessment of coronary artery patency after thrombolytic therapy: accurate prediction utilizing the combined

analysis of three noninvasive markers. J Am Coll Cardiol 1991; 18: 44-49.

274. Stewart JT, French JK, Theroux P, et al. Early noninvasive identification of failed reperfusion after intravenous thrombolytic therapy in acute myocardial

infarction. J Am Coll Cardiol 1998; 31: 1499-1505.

275. Lee S, Otsuji Y, Minagoe S, et al. Correlation between distal left anterior descending artery flow velocity by transthoracic Doppler echocardiography

and corrected TIMI frame count before mechanical reperfusion in patients with anterior acute myocardial infarction. Circ J 2005; 69: 1022-1028.

276. The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. TIMI Study Group. N Engl J Med 1985; 312: 932-936.

277. Gibson CM, Cannon CP, Daley WL, et al. TIMI frame count: a quantitative method of assessing coronary artery flow. Circulation 1996; 93: 879-888.

278. Ito H, Tomooka T, Sakai N, et al. Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left

ventricular function in anterior myocardial infarction. Circulation 1992; 85: 1699-1705.

279. van't Hof AW, Liem A, Suryapranata H, et al. Angiographic assessment of myocardial reperfusion in patients treated with primary angioplasty for acute

myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 1998; 97: 2302-2306.

280. Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs.

Circulation 2000; 101: 125-130.

281. Yamamuro A, Akasaka T, Tamita K, et al. Coronary flow velocity pattern immediately after percutaneous coronary intervention as a predictor of

complications and in-hospital survival after acute myocardial infarction. Circulation 2002; 106: 3051-3056.

282. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007; 357: 1121-1135.

283. Ishihara M, Sato H, Tateishi H, et al. Implications of prodromal angina pectoris in anterior wall acute myocardial infarction: acute angiographic findings

and long-term prognosis. J Am Coll Cardiol 1997; 30: 970-975.

284. Yang XM, Proctor JB, Cui L, et al. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling

pathways. J Am Coll Cardiol 2004; 44: 1103-1110.

285. Botker HE, Kharbanda R, Schmidt MR, et al. Remote ischaemic conditioning before hospital admission, as a complement to angioplasty, and effect

on myocardial salvage in patients with acute myocardial infarction: a randomised trial. Lancet 2010; 375: 727-734.

286. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease.

The RISC Group. Lancet 1990; 336: 827-830.

287. Granger CB, Miller JM, Bovill EG, et al. Rebound increase in thrombin generation and activity after cessation of intravenous heparin in patients with

acute coronary syndromes. Circulation 1995; 91: 1929-1935.

288. Theroux P, Waters D, Lam J, et al. Reactivation of unstable angina after the discontinuation of heparin. N Engl J Med 1992; 327: 141-145.

289. Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated

heparin. N Engl J Med 1995; 332: 1330-1335.

290. Eikelboom JW, Quinlan DJ, Mehta SR, et al. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients

with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 2005; 112: 3855-3867.

291. Sabatine MS, Morrow DA, Montalescot G, et al. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus

unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 Trial. Circulation 2005; 112: 3846-

3854.

292. Kereiakes DJ, Montalescot G, Antman EM, et al. Low-molecularweight heparin therapy for non-ST-elevation acute coronary syndromes and during

percutaneous coronary intervention: an expert consensus. Am Heart J 2002; 144: 615-624.

293. Long-term low-molecular-mass heparin in unstable coronaryartery disease: FRISC II prospective randomised multicentre study. FRagmin and Fast

Revascularisation during InStability in Coronary artery disease. Investigators. Lancet 1999; 354: 701-707.

294. Silvain J, Beygui F, Barthelemy O, et al. Efficacy and safety of enoxaparin versus unfractionated heparin during percutaneous coronary intervention:

systematic review and meta-analysis. BMJ 2012; 344: e553.

295. Brieger D, Collet JP, Silvain J, et al. Heparin or enoxaparin anticoagulation for primary percutaneous coronary intervention. Catheter Cardiovasc Interv

2011; 77: 182-190.

296. Jang IK, Brown DF, Giugliano RP, et al. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator

(TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study. J Am Coll Cardiol 1999; 33: 1879-1885.

297. Cruz-Gonzalez I, Sanchez-Ledesma M, Baron SJ, et al. Efficacy and safety of argatroban with or without glycoprotein IIb/IIIa inhibitor in patients with

heparin induced thrombocytopenia undergoing percutaneous coronary intervention for acute coronary syndrome. J Thromb Thrombolysis 2008; 25:

214-218.

298. 松尾武文．ヘパリン起因性血小板減少症（HIT）の診断と治療について教えて下さい．血栓と循環 2005; 13: 170-173.

299. Mehta SR, Granger CB, Eikelboom JW, et al. Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes

undergoing percutaneous coronary intervention: results from the OASIS-5 trial. J Am Coll Cardiol 2007; 50: 1742-1751.

300. Yusuf S, Mehta SR, Chrolavicius S, et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial

infarction: the OASIS-6 randomized trial. JAMA 2006; 295: 1519-1530.

文献